(GMT-05:00) Eastern Time (US & Canada)
45 minutes
Across 2020 and 2021, 149 biotech companies went public nationally at offerings over $50 million. These companies continued a trend of more companies going public through an IPO earlier in their life-cycle – the median time from founding to IPO has gone from 10 years in 2013 to only 4 years in 2021. Going public is a major milestone, but much lies ahead. This panel of experts will discuss life after after an IPO, especially during the current market downturn.
Across 2020 and 2021, 149 biotech companies went public nationally at offerings over $50 million. These companies continued a trend of more companies going public through an IPO earlier in their life-cycle – the median time from founding to IPO has gone from 10 years in 2013 to only 4 years in 2021. Going public is a major milestone, but much lies ahead. This panel of experts will discuss life after after an IPO, especially during the current market downturn.

Speakers

Daphne Zohar - Founder and CEO, PureTech
Jami Rubin - Chief Financial Officer, EQRx
Lloyd M. Segal - President and CEO, Repare Therapeutics
Nathan Jorgenson, Ph.D. - Chief Financial Officer, Vor Biopharma
Teo Forcht Dagi, MD, DMedSc, DHC, MBA, MPH, FRCSEd - Neurosurgeon and Venture Capitalist
Tracks
Name Audience
Business Track